Viewing Study NCT02556632


Ignite Creation Date: 2025-12-24 @ 9:30 PM
Ignite Modification Date: 2025-12-31 @ 5:40 AM
Study NCT ID: NCT02556632
Status: COMPLETED
Last Update Posted: 2017-11-06
First Post: 2015-07-23
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Sponsor: Gary Morrow
Organization:

Study Overview

Official Title: Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis
Status: COMPLETED
Status Verified Date: 2017-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: Curcumin-II
Brief Summary: This randomized pilot phase II trial studies and compares prophylactic topical agents in reducing radiation-induced dermatitis in patients with non-inflammatory breast cancer or breast cancer in situ. The prophylactic topical agents, such as curcumin-based gel or HPR Plus, may reduce the severity of the radiation-induced dermatitis by minimizing water loss and inflammation during radiation therapy.
Detailed Description: PRIMARY OBJECTIVE:

I. To investigate the effectiveness of Curcumin gel (curcumin-based gel) or HPR Plus™ in reducing radiation dermatitis in breast cancer patients.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
NCI-2015-00869 REGISTRY CTRP (Clinical Trial Reporting Program) View
URCC14079 OTHER University of Rochester NCORP Research Base View
URCC-14079 OTHER DCP View
R21CA178648 NIH None https://reporter.nih.gov/quic… View
UG1CA189961 NIH None https://reporter.nih.gov/quic… View